Ocugen (OCGN) Cash from Financing Activities (2014 - 2026)
Ocugen's (OCGN) quarterly Cash from Financing Activities came in at $35.0 million in Q1 2026, up 2909.96% YoY from $1.2 million in Q1 2025, and up 1749100.0% on a QoQ basis from $2000.0 in Q4 2025.
Ocugen (OCGN) Cash from Financing Activities (2014 - 2026) Analysis & Trends
Ocugen (OCGN) has 13 years of Cash from Financing Activities data on file, last reported at $35.0 million in Q1 2026.
- Quarterly Cash from Financing Activities rose 2909.96% year-over-year to $35.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $53.6 million (down 16.0% YoY) and the FY2025 annual result came in at $17.3 million, down 73.28% from the prior year.
- Cash from Financing Activities improved to $35.0 million in Q1 2026, from $2000.0 in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $50.1 million in Q1 2022 to a low of -$1.2 million in Q1 2025.
- A 5-year average of $11.6 million and a median of $962000.0 in 2022 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2024 — Cash from Financing Activities surged 188475.0% — and 2025, when it sank 758.62%.
- Tracing OCGN's Cash from Financing Activities over 5 years: stood at $8.2 million in 2022, then sank by 99.8% to $16000.0 in 2023, then surged by 188475.0% to $30.2 million in 2024, then sank by 99.99% to $2000.0 in 2025, then jumped by 1749100.0% to $35.0 million in 2026.
- The last three Cash from Financing Activities figures came in at $35.0 million (Q1 2026), $2000.0 (Q4 2025), and $18.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Ocugen | 457.71 Mn | 357.61 Mn | - | 80.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 80.37 Mn |
| Jun 30, 2026 | 80.37 Mn |
| Mar 31, 2026 | 34.98 Mn |
| Mar 31, 2026 | 34.98 Mn |
| Dec 31, 2025 | 2,000.00 |
| Dec 31, 2025 | 2,000.00 |
| Sep 30, 2025 | 18.51 Mn |
| Sep 30, 2025 | 18.51 Mn |
| Jun 30, 2025 | 61,000.00 |
| Jun 30, 2025 | 61,000.00 |
| Mar 31, 2025 | -1.25 Mn |
| Mar 31, 2025 | -1.25 Mn |
| Dec 31, 2024 | 30.17 Mn |
| Dec 31, 2024 | 30.17 Mn |
| Sep 30, 2024 | 34.79 Mn |
| Sep 30, 2024 | 34.79 Mn |
| Jun 30, 2024 | 45,000.00 |
| Jun 30, 2024 | 45,000.00 |
| Mar 31, 2024 | -145,000.00 |
| Mar 31, 2024 | -145,000.00 |